Yaral Pharma, the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector (diclofenac epolamine) topical system.

Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

“We are excited to kick off the new year by launching the first of several products in our portfolio which includes authorized and complex generic medications,” said Stephen Beckman, CEO, Yaral Pharma. “Like Flector, Yaral Pharma’s diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment backed by more than 30 years of clinical experience. We are pleased to offer patients an accessible and affordable product that offers targeted topical pain relief and look forward to expanding our product line across a range of therapeutic areas in the months ahead.”